Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

A Mount Sinai team showed that the same leukemia mutation behaves differently depending on when it arises during development.

A recent study in the journal PNAS from the lab of Julie Overbaugh reveals a previously unknown antiviral function of a gene ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

In cooperation with universities, the Center of Estonian Rural Research and Knowledge (METK) is leading a project aimed at ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR screens often mislead cancer research because bacterial Cas9 components trigger immune reactions in mice. ETH Zurich researchers developed a “stealth” CRISPR approach that removes immunogenic ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

The CRISPR gene editing technique has had a dramatic influence on biomedical research, and has even been applied to a few ...